EDVA SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 19, 2026

NT 10-Q

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Aug 17, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 20, 2026

NT 10-Q

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

May 15, 2026

10-K/A

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Apr 30, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Apr 15, 2026

News

TYPE

HEADLINE

FILED AT

8-K

Endovia Health Sciences Amends ELOC Agreement to Increase Commitment to $135 Million

Oct 27, 2026

8-K

Endovia Health Sciences Amends Purchase Agreement with C/M Capital Master Fund to Increase Beneficial Ownership Limitation

Oct 15, 2026

8-K

Endovia Health Sciences Reports Unregistered Sale of Common Stock

Oct 6, 2026

8-K

Endovia and Lupvindol Announce FDA Minor Use Determination for CannEpil® in Canine Bone Cancer Pain

Oct 5, 2026

8-K

Endovia Health Sciences Enters $1 Million Investment Agreement and Closes Initial $510,000 Note

Sep 24, 2026

8-K

Endovia Health Sciences Closes Initial $500,000 Financing for CannEpil® Development

Sep 22, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

SHARE RESALE REGISTRATION | Offering amount: $29,800,324 | Shares: 1,013,041

Nov 3, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 5,000,000

Aug 28, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 10,000,000

Jun 26, 2026

424B3

PENDING FIXED PRICE OFFERING | Shares: 10,000,000

Jan 26, 2026

424B3

PENDING FIXED PRICE OFFERING | Shares: 10,000,000

Jan 23, 2026

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 7,765,238 | Warrants amount: 75,000

Jan 6, 2026

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Nov 2, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Oct 23, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Oct 7, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Oct 5, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Sep 23, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Sep 18, 2026

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

C/M CAPITAL PARTNERS, LP (Filed by)

Oct 22, 2026

Bondurant Michael Breen (Reporting)

Jun 18, 2026

Bondurant Michael Breen (Reporting)

Jun 15, 2026

Fore Thomas Butler (Reporting)

Jun 10, 2026

Caple Frederick William (Reporting)

Jun 10, 2026

Francis Knuettel II (Reporting)

Jun 10, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 4, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 25, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 23, 2026

CORRESP

Form CORRESP - Correspondence

Jun 17, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jun 17, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 30, 2025

Endovia Health Sciences, Inc. EDVA · SEC Filings